By Lynda Williams, medwireNews Reporter
medwireNews: Patients with deficient mismatch repair cancers may not require surgery after 6 months of neoadjuvant treatment with the PD-1 inhibitor dostarlimab, suggests research published in The New England Journal of Medicine.
This independent news story was supported by an educational grant from L’Institut Servier, Suresnes, France.
Read the full story on the L’Institut Servier website
Image credit: © bymuratdeniz / Getty Images / iStock
